Multi-drug resistance in vertically infected children
6 December 2006. Related: Conference reports, Paediatric care, Resistance.
Resistance
MK-0518 demonstrates potent efficacy in patients with triple-class resistant virus: 24 week results
7 October 2006. Related: Conference reports, Resistance.
Cell studies predict cross-resistance among integrase inhibitors
7 October 2006. Related: Conference reports, Resistance.
Report from the 10th Annual UK Resistance Meeting, 21 September 2006, London
7 October 2006. Related: Conference reports, Resistance.
15th International Drug Resistance Workshop, 13-17 June 2006, Sitges, Spain
3 August 2006. Related: Conference reports, Resistance.
Resistance implications of monotherapy with lopinavir/r (Kaletra)
3 August 2006. Related: Conference reports, Resistance.
Ritonavir reduces virological failure and resistance in treatment naive patients treated with atazanavir
3 August 2006. Related: Conference reports, Resistance.
Resistance to darunavir (TMC-114): predicting responses for treatment experienced patients
3 August 2006. Related: Conference reports, Resistance.
Epidemiological studies and transmission of resistance: evidence for optimism or issues with interpretation?
3 August 2006. Related: Conference reports, HIV prevention and transmission, Resistance.
K103N containing variants persist longer in women with subtype D and with higher viral loads
3 August 2006. Related: Conference reports, Resistance.
No subtype-based differences in baseline levels of K103N-containing variants in women receiving single dose nevirapine
3 August 2006. Related: Conference reports, Resistance.
Phenotypic NNRTI resistance and genetic diversity in antiretroviral naive women
3 August 2006. Related: Conference reports, Resistance.
High prevalence of the K65R mutation in Botswana patients treated with ddI/d4T-based regimens
3 August 2006. Related: Conference reports, Resistance.
Potential for easier selection of K65R mutation with tenofovir pressure in subtype C HIV-1 isolates
3 August 2006. Related: Conference reports, Resistance.
Categorisation of transmitted HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method may be useful in resource limited settings
3 August 2006. Related: Conference reports, Resistance.
Limitations in online tools to identify HIV-1 subtypes
3 August 2006. Related: Conference reports, Resistance.
Resistance implications from PrEP and microbicide studies in macaques
3 August 2006. Related: Conference reports, Resistance.
Low-level resistance linked to treatment failure: a role for more sensitive testing for naive patients
3 August 2006. Related: Conference reports, Resistance.
Testing for resistance after starting treatment
3 August 2006. Related: Conference reports, Resistance.
Web resources for HIV-1 genotypic-resistance test interpretation
10 June 2006. Related: Resistance.
Association between HIV subtype and detection of K103N
13 April 2006. Related: Conference reports, Pregnancy, Resistance.
Cost effectiveness of resistance testing for treatment-naive patients
13 December 2005. Related: Resistance.
Highlights of HIV drug resistance studies presented at the 3rd IAS Conference
13 October 2005. Related: Conference reports, Resistance.
Interaction between tenofovir and ddI in triple-nucleoside combinations: role of M184V in explaining resistance on failure
14 July 2005. Related: Conference reports, Resistance.
Predicting clinical responses to ddI from genotypic resistance
14 July 2005. Related: Conference reports, Resistance.
Under-detection of transmission of transmitted resistance and impact on treatment response
14 July 2005. Related: Conference reports, Resistance.
Risk of death in UK after diagnosis of 3-class resistance
14 July 2005. Related: Conference reports, Resistance.
Tenofovir, nucleosides, and non-nucleosides
15 May 2005. Related: Conference reports, Resistance.
Protease inhibitors
15 May 2005. Related: Conference reports, Resistance.
CCR5 antagonists
15 May 2005. Related: Conference reports, Resistance.
Another chance for 3TC in patients with M184V mutation?
6 September 2004. Related: Conference reports, Antiretrovirals, Treatment strategies, Resistance.
Risk of NNRTI-resistance during STI: implications for SMART and other STI studies
29 July 2004. Related: Conference reports, Resistance.
Persistent nevirapine resistance following mother to child transmission interventions
29 July 2004. Related: Conference reports, Pregnancy, Resistance.
Tipranavir resistance and viral response: L90M did not reduce response, recommendation to use with T-20
29 July 2004. Related: Conference reports, Pregnancy, Resistance, Other news.
Resistance in the UK: new approach to epidemiological studies
29 July 2004. Related: Conference reports, Resistance.
Low AZT activity against HIV-2 infection
29 July 2004. Related: Conference reports, Resistance.
No evidence for cross resistance between nevirapine and d4T
29 July 2004. Related: Conference reports, Resistance.
Experimental compounds to target viral expression in latent cells
29 July 2004. Related: Conference reports, Antiretrovirals, Resistance.
Case of MDR reinfection with MDR virus
29 July 2004. Related: Conference reports, Resistance.
Kaletra therapy fails woman with subtype C virus with multiple mutations
2 June 2004. Related: Resistance.
Understanding developments in HIV drug resistance for new drugs and targets — atazanavir, fusion (T-20) and receptor inhibitors
2 May 2004. Related: Conference reports, Resistance.
Summary of resistance studies at Retrovirus
3 April 2004. Related: Conference reports, Resistance.
XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, 10-14 June 2003
1 September 2003. Related: Conference reports, Resistance.
Transmission of drug resistance – at 11% in Europe and 17% in the UK
1 September 2003. Related: Conference reports, HIV prevention and transmission, Resistance.
HIV coinfection, reinfection and superinfection
1 September 2003. Related: Conference reports, Hepatitis coinfection, HIV prevention and transmission, Resistance.
Single-dose nevirapine resistance in over 75% of mothers
1 September 2003. Related: Conference reports, Women's health, Pregnancy, Resistance.
Transmission of drug resistant virus does not revert to wild-type and does not appear ‘less fit’
1 September 2003. Related: Conference reports, Resistance.
Standard genotype assays may miss 75% of mutations when present in less than 35% of plasma sample
1 September 2003. Related: Conference reports, Resistance.
Low-level resistance and minority populations: cross resistance between nevirapine and efavirenz occurs even in the absence of genotypic mutations found using population sequencing
1 September 2003. Related: Conference reports, Resistance.
Persistent effect of d4T and 3TC, but not NNRTIs in the presence of associated genotypic mutations
1 September 2003. Related: Conference reports, Resistance.
Replicative capacity results complicated by minority wild-type virus
1 September 2003. Related: Conference reports, Virology, Resistance.
Tenofovir, resistance and K65R and concomitant nucleosides
1 September 2003. Related: Conference reports, Antiretrovirals, Resistance.
Response to STI is determined by virus rather than immunological response
1 September 2003. Related: Conference reports, Resistance.
Why resistance rarely develops with viral suppression <50 copies/mL
1 September 2003. Related: Conference reports, Resistance.
Long-term persistence of distinct mutations in genital tract
1 September 2003. Related: Conference reports, Women's health, Resistance.
Resistance summary of new PIs: atazanavir and tipranavir
1 September 2003. Related: Resistance.
Study reveals new reverse transcriptase mutations
1 May 2003. Related: Resistance.
Nevirapine resistance – the cautionary tales continue
1 April 2003. Related: Conference reports, Pregnancy, Resistance.
Subtle decreases in stavudine (d4t, Zerit) phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine (AZT, Retrovir)-experienced patients
1 March 2003. Related: Resistance.
Medical care providers have very limited knowledge of resistance-associated drug mutations
1 March 2003. Related: Resistance.
Inhibitory quotient useful as indicator of effective protease inhibitor therapy
1 March 2003. Related: Resistance.
The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates
1 February 2003. Related: Conference reports, Antiretrovirals, Treatment strategies, Hepatitis coinfection, Resistance.
Enfuvirtide (T-20): predicting success and modelling survival benefits
1 February 2003. Related: Conference reports, Antiretrovirals, Resistance.
M184V is associated with decreased development of TAMs
13 October 2002. Related: Resistance.
Short resistance reports from Seville
11 September 2002. Related: Conference reports, Resistance.